Davide Capodanno/X
Jul 8, 2025, 07:56
AUREA – No Added Benefit of Short-Term OAC Post-TAVI in Patients Without OAC Indication
Davide Capodanno, Professor of Cardiology at University of Catania, Italy has posted on X:
“In the randomized, open-label AUREA trial, an OAC strategy for 3 months post-TAVI did not show any benefit over an antiplatelet strategy in preventing cerebral microembolism in patients without an indication for OAC. Patients treated with DAPT showed a lower mean volume of brain damage on DW-MRI during the 90 days following TAVI compared to those treated with acenocoumarol.”

You can read the Full Article here.
Explore more on Hemostasis Today.
-
Aug 26, 2026, 17:46Bruno Pougault: The Hidden Burden of Hemostatic Disorders in Women
-
Aug 26, 2026, 17:39Charan Gubba: Adult ITP – A major shift in the 2026 ASH Guidelines
-
Aug 26, 2026, 17:38Stephan A Mayer: Early Imaging Reveals Higher Risk of Hematoma Expansion After ICH
-
Aug 26, 2026, 17:09Kemal Karaagac: NOACs May Offer Cognitive and Clinical Benefits in AF With Alzheimer’s Disease
-
Aug 26, 2026, 16:53Chokri Ben Lamine: Antiphospholipid Syndrome After Kidney Transplantation
-
Aug 26, 2026, 16:32Kai Rejeski: Why TP53 Mutations May Define a Higher-Risk CAR-T Population
-
Aug 26, 2026, 16:20Ons Marsit: Impact of Electroanatomical Mapping on Pentaspline Pulsed Field Ablation
-
Aug 26, 2026, 16:18Sam Mbunya: Celebrating Cyrus Njuguna Githinji’s New Leadership Role in Haemophilia Care
-
Aug 26, 2026, 15:48Melissa Hollo: Postpartum Depression is More Than the “Baby Blues”